ES2152313T3 - Gen grb-3-3, sus variantes y sus utilizaciones. - Google Patents

Gen grb-3-3, sus variantes y sus utilizaciones.

Info

Publication number
ES2152313T3
ES2152313T3 ES94915598T ES94915598T ES2152313T3 ES 2152313 T3 ES2152313 T3 ES 2152313T3 ES 94915598 T ES94915598 T ES 94915598T ES 94915598 T ES94915598 T ES 94915598T ES 2152313 T3 ES2152313 T3 ES 2152313T3
Authority
ES
Spain
Prior art keywords
variants
grb
gen
anticanceric
grb3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94915598T
Other languages
English (en)
Inventor
Fabien Schweighoffer
Bruno Tocque
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Application granted granted Critical
Publication of ES2152313T3 publication Critical patent/ES2152313T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN NUEVO GEN, LLAMADO GRB3-3, SUS VARIANTES Y SUS UTILIZACIONES,PARTICULARMENTE EN TERAPIA GENICA ANTICANCEROSA.
ES94915598T 1993-09-15 1994-05-09 Gen grb-3-3, sus variantes y sus utilizaciones. Expired - Lifetime ES2152313T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9310971A FR2710074B1 (fr) 1993-09-15 1993-09-15 Gène GRB3-3, ses variants et leurs utilisations.

Publications (1)

Publication Number Publication Date
ES2152313T3 true ES2152313T3 (es) 2001-02-01

Family

ID=9450882

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94915598T Expired - Lifetime ES2152313T3 (es) 1993-09-15 1994-05-09 Gen grb-3-3, sus variantes y sus utilizaciones.

Country Status (27)

Country Link
US (2) US5831048A (es)
EP (1) EP0719328B1 (es)
JP (1) JP3794697B2 (es)
KR (1) KR100330477B1 (es)
CN (1) CN1098930C (es)
AT (1) ATE196926T1 (es)
AU (1) AU698819B2 (es)
BR (1) BR9407693A (es)
CA (1) CA2169938A1 (es)
CZ (1) CZ288882B6 (es)
DE (1) DE69426121T2 (es)
DK (1) DK0719328T3 (es)
ES (1) ES2152313T3 (es)
FI (1) FI120499B (es)
FR (1) FR2710074B1 (es)
GR (1) GR3034600T3 (es)
HU (1) HU221516B (es)
IL (2) IL126756A (es)
NO (1) NO319144B1 (es)
NZ (1) NZ266162A (es)
PL (1) PL178402B1 (es)
PT (1) PT719328E (es)
RU (1) RU2159815C2 (es)
SK (1) SK281123B6 (es)
UA (1) UA46715C2 (es)
WO (1) WO1995007981A1 (es)
ZA (1) ZA947059B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732348B1 (fr) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Systeme d'expression conditionnel
US6171800B1 (en) 1995-06-07 2001-01-09 Biogen, Inc. Method of making and binding CAIP polypeptides
US5837844A (en) * 1995-06-07 1998-11-17 Biogen, Inc. CAIP-like gene family
US6423824B1 (en) 1995-06-07 2002-07-23 Biogen, Inc. CAIP-like gene family
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
WO1997049808A1 (en) * 1996-06-27 1997-12-31 Biogen, Inc. The caip-like gene family
US7309692B1 (en) * 1996-07-08 2007-12-18 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
EP0998945A1 (en) * 1998-09-30 2000-05-10 Transgene S.A. Use of magnesium (Mg2+) for the enhancement of gene delivery in gene therapy
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
US20040259247A1 (en) 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
CA2471967A1 (en) * 2002-01-03 2003-07-31 Board Of Regents, The University Of Texas System Wt1 antisense oligos for the inhibition of breast cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE920151A1 (en) * 1991-01-18 1992-07-29 Univ New York A novel expression-cloning method for identifying target¹proteins for receptor tyrosine kinases and novel human grb¹proteins
AU5136093A (en) * 1992-09-25 1994-04-26 Warner-Lambert Company Peptide antagonists of sh2 binding and therapeutic uses thereof

Also Published As

Publication number Publication date
GR3034600T3 (en) 2001-01-31
PL178402B1 (pl) 2000-04-28
IL110942A0 (en) 1994-11-28
SK34596A3 (en) 1996-07-03
FR2710074B1 (fr) 1995-12-08
NO960965L (no) 1996-03-08
CZ288882B6 (cs) 2001-09-12
CZ75896A3 (en) 1996-06-12
AU6724794A (en) 1995-04-03
CN1098930C (zh) 2003-01-15
ATE196926T1 (de) 2000-10-15
WO1995007981A1 (fr) 1995-03-23
USRE37952E1 (en) 2002-12-31
AU698819B2 (en) 1998-11-05
HU9600668D0 (en) 1996-05-28
DE69426121D1 (de) 2000-11-16
NO960965D0 (no) 1996-03-08
FI961202L (fi) 1996-03-14
US5831048A (en) 1998-11-03
NO319144B1 (no) 2005-06-27
DE69426121T2 (de) 2001-05-31
UA46715C2 (uk) 2002-06-17
NZ266162A (en) 1997-11-24
JP3794697B2 (ja) 2006-07-05
FR2710074A1 (fr) 1995-03-24
EP0719328B1 (fr) 2000-10-11
EP0719328A1 (fr) 1996-07-03
HUT74273A (en) 1996-11-28
FI120499B (fi) 2009-11-13
IL126756A (en) 2006-06-11
ZA947059B (en) 1995-05-18
CA2169938A1 (fr) 1995-03-23
PL313445A1 (en) 1996-07-08
BR9407693A (pt) 1997-02-04
IL110942A (en) 2001-12-23
HU221516B (hu) 2002-11-28
SK281123B6 (sk) 2000-12-11
FI961202A0 (fi) 1996-03-14
PT719328E (pt) 2001-02-28
KR100330477B1 (ko) 2002-12-02
RU2159815C2 (ru) 2000-11-27
DK0719328T3 (da) 2000-11-13
CN1133064A (zh) 1996-10-09
JPH09502357A (ja) 1997-03-11

Similar Documents

Publication Publication Date Title
HN1998000132A (es) Combinaciones terapeuticas
ES2152313T3 (es) Gen grb-3-3, sus variantes y sus utilizaciones.
ES2182906T3 (es) Grapa quirurgica helicoidal.
HN1998000175A (es) Imidazotriazininas
CA98120S (en) Arch support insole
GB2382110A (en) Clutch assembly
HN1997000099A (es) Inhibidores de metaloproteasas matriciales basados en
ES2146886T3 (es) Inhibidores de la selectina de moleculas pequeñas bivalentes y trivalentes.
GEP20105118B (en) Anti-vegf antibodies
HN1998000002A (es) Compuestos de quinolina y de quinazolina utiles en terapia
PL308122A1 (en) Viral vectors and their application in genic therapy
AU144678S (en) Bottle
ES2110386T3 (es) Conjugados de interferon.
EP0623171A4 (en) ENZYMATIC RNA MOLECULES.
HN1997000012A (es) Derivados de triazol utiles en terapia.
HN1998003689A (es) Azetidinas
ATE332366T1 (de) Dipeptidyl-peptidasen
DK0774005T3 (da) Overfladeudtrykkelse af enzymer i genorienteret prodrug-terapi
ATE476495T1 (de) Bazillus thuringiensis und dessen insektizide proteine
CA98142S (en) Ink cartridge
ATE205241T1 (de) Staubkontrollzusammensetzung
MY114140A (en) Novel enzymes and prodrugs for use in antibody-directed enzyme prodrug therapy.
BR0005568A (pt) Lentes de contato com bordas contornadas
FR2694623B1 (fr) Brûleurs oxycombustibles.
BG101401A (bg) Състави за орално приложение с удължено освобождаване на цисаприд

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 719328

Country of ref document: ES